Draft PMDA-ATC Pharmacovigilance Seminar 2020

Offered by Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC) Date: February 3 - 6, 2020 Venue: PMDA Meeting rooms #21-23 (14th floor)

| | Day 1 February 3 (Mon) | Day 2 February 4 (Tue) | Day 3 February 5 (Wed) | Day 4 February 6 (Thu) |
|-------|---|--|--|---|
| | 9:15-9:45 | 9:10-9:20 Opening | 9:20-9:30 Opening | 9:20-9:30 Opening |
| | Registration | 9:20 - 12:10 | 9:30-10:30 | 9:30-10:45 |
| | 9:45 - 10:00 | (5) Risk minimization measures: Labeling | (8)Evaluation of Benefit/Risk Balance | (11) Pharmacovigilance and |
| | Opening Ceremony, Overview of the Seminar | management | throughout Product Lifecycle, | Pharmacoepidemiology |
| | opening ceremony, overview of the Seminar | - End-to-End Labeling process: CCDS/CCSI | Assessment of effectiveness of risk | |
| | | Labeling system, Management of Labeling in | minimization activities | |
| | | Asia, electronic labeling initiatives | | |
| | 10:00 - 10:45 | - Management of USPI and Medication guide | 10.30-10.40 | 10:45-11:00 |
| AM | (1) Outline of PMDA | - Management of EUSmPC and package | Break | Break |
| | | leaflet | 10:40-11:40 | 11:00 - 12:00 |
| | | - Management of Japan Package Insert, | | |
| | 10:45 - 12:15 | patient medication guide | (9) Communication of Safety Risk Information | |
| | (2) Comparison of Pharmacovigilance systems | patient medication guide | to Patients and Healthcare Professioals | for Drug Safety Assessment in PMDA - |
| | among the US, Europe and Japan and | | involvement | |
| | International Cooperation | | | |
| | | | | |
| | | | | |
| | | | | |
| Lunch | (1 hour 30min. Starting time varies.) | | | |
| РМ | 13:45 - 14:45 | 13:40 - 15:10 | 13:10 - 16:30 | 13:30 - 14:40 |
| | (3) Pharmacovigilance in the US | (6) Risk Management Plan - Practice at | (10) Group Work:RMP (Risk Minimization | (13) Healthcare Professionals involvement |
| | | Industry and Regulatory | Activity) | • ADR reporting by Healthcare Professionals |
| | | •Overview (PMDA) | - How to Create RMP – Planning Risk | • The use of safety information by Healthcare |
| | | •Industory | Minimization Activity | Professionals |
| | | •Regulatory | | |
| | | negulatory | | |
| | | | | |
| | 14:45 - 15:00 | 15:10 - 15:25 | | 14:40 - 14:50 |
| | Break | Break | | Break |
| | 15:00 - 17:15 | 15:25 - 17:45 | | 14:50 - 15:50 |
| | (4) Introduction of Pharmacovigilance in Each | | | (14) Relief System for Adverse Drug Reactions |
| | Country/Region | - How to create RMP – Identification of | | |
| | | Safety Specifications | | 15:50 - 16:00 |
| | | Surery Specifications | | Break |
| | | | 16:30 - 16:45 | 16:00 - 16:30 |
| | | | Closing | Closing Ceremony |
| | 17:15 - 17:30 | 17:45 - 18:00 | | citering eccentering |
| | Closing | Closing | | |
| | | |] | |
| | 17:30 - | | | |
| | Friendly Get Together | | | |